HARRISON F. FLIPPIN, M.D.; LEON SCHWARTZ, M.D.; S. BRANDT ROSE, M.D.
Following the discovery that sulfapyridine was an effective agent in treating experimental and clinical infections due to the pneumococcus, chemotherapy of pneumococcic pneumonia has received widespread attention during the past two years. Within this time numerous1 clinical reports unquestionably have established the therapeutic effectiveness of sulfapyridine in pneumonia. However, it is generally recognized that sulfapyridine therapy is not ideal because nausea and vomiting often interfere with adequate treatment. Furthermore, serious toxic manifestations, such as blood dyscrasias and renal complications, may occur.
Within recent months there has become available a new sulfanilamide derivative, sulfathiazole,3 which we have used in the treatment
FLIPPIN HF, SCHWARTZ L, ROSE SB. THE COMPARATIVE EFFECTIVENESS AND TOXICITY OF SULFATHIAZOLE AND SULFAPYRIDINE IN PNEUMOCOCCIC PNEUMONIA1. Ann Intern Med. ;13:2038–2049. doi: 10.7326/0003-4819-13-11-2038
Download citation file:
Published: Ann Intern Med. 1940;13(11):2038-2049.
Emergency Medicine, Healthcare Delivery and Policy, Infectious Disease, Pneumonia, Pulmonary/Critical Care.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use